Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Position Lifted by New York State Common Retirement Fund

New York State Common Retirement Fund grew its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 2.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 189,101 shares of the company’s stock after acquiring an additional 5,170 shares during the quarter. New York State Common Retirement Fund’s holdings in Castle Biosciences were worth $5,040,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. increased its stake in Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after purchasing an additional 40,377 shares during the last quarter. Bellevue Group AG raised its stake in Castle Biosciences by 3.7% during the third quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock worth $35,993,000 after acquiring an additional 44,929 shares during the period. Portolan Capital Management LLC lifted its holdings in Castle Biosciences by 3.7% in the third quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock worth $35,811,000 after acquiring an additional 44,676 shares during the last quarter. State Street Corp boosted its stake in Castle Biosciences by 9.8% in the third quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after acquiring an additional 60,924 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Castle Biosciences by 1.1% during the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock valued at $17,820,000 after purchasing an additional 7,004 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Stock Down 3.1 %

Castle Biosciences stock opened at $25.22 on Friday. The company’s 50-day moving average price is $27.35 and its two-hundred day moving average price is $29.19. The stock has a market cap of $706.34 million, a price-to-earnings ratio of 126.11 and a beta of 0.91. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CSTL. Lake Street Capital raised their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. KeyCorp boosted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Scotiabank increased their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 6th. Stephens reiterated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 2nd. Finally, Robert W. Baird upped their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $40.29.

Insider Buying and Selling

In other news, insider Derek J. Maetzold sold 1,972 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $31.35, for a total transaction of $61,822.20. Following the completion of the transaction, the insider now owns 85,748 shares in the company, valued at approximately $2,688,199.80. This trade represents a 2.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Insiders have sold a total of 30,771 shares of company stock valued at $886,112 over the last quarter. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.